Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Novo Nordisk

Main (gene editing) focus: Gene therapies and gene editing for the treatment of genetic blood diseases

Company stage: Commercial

Diseases (gene editing): Haemophilia and other severe genetic diseases

Genome editing tool: megaTAL

Funding stage: Public (NASDAQ:NOVO)

Location: Bagsvaerd, Denmark



Gene editing partnerships: bluebird bio, SNIPR Biome

Novo Nordisk is a big pharma company, developing therapies within the areas of diabetes, obesity, cardiovascular diseases, blood diseases and liver diseases. The company is mainly involved in the gene-editing space through its partnership with bluebird bio. These two companies have agreed to jointly develop next generation in vivo genome-editing treatments for genetic diseases including haemophilia, using bluebird's proprietary megaTAL gene-editing technology. Novo Nordisk also has a collaboration with microbiome-focused Danish company SNIPR Biome.


HashtagNovo Nordisk

Company: Novo Nordisk
Search CRISPR Medicine